Investor Relations

Board of Directors

Executive Directors

Dr. Ray Yip (“Dr. Yip”), aged 67, is a non-executive Director. Dr. Yip joined the Group in February 2017. He is also a member of each of the Audit Committee, Nomination Committee and Remuneration Committee of the Company. He is an international public health leader who has made a significant contribution to global health in the areas of nutrition, maternal and child health, HIV/AIDS and tobacco control. Dr. Yip has been working on emergency response to war and famine, long term program and policy development effort in the PRC in recent years. Dr. Yip was the founding director of the Chinese office of U.S. Centers for Disease Control and Prevention (the “CDC”) in 2013, and the China program director of the Bill and Melinda Gates Foundation(the “Foundation”) in 2017. Dr. Yip is known as a specialist for health and medical issues in the PRC.

Dr. Yip’s major contributions to the global health include: refining the international criteria for screening for malnutrition and anemia and increasing the awareness of diarrhea as a major contributor to acute malnutrition. His work in the PRC has resulted in the mainstreaming of hepatitis B vaccine for routine immunization, the adoption of hospital- based delivery as a strategy which significantly reduced maternal mortality, transformation of the national AIDS response to one targeting those high-risk groups by accepting the role of civil society and assisting in engineering the policy support for tobacco control at the top level.

Dr. Yip established the Foundation’s mission in China by assisting the government in addressing the key public health issues such as HIV and tobacco. He also transformed the Foundation’s strategy in giving it a new focus “China-for-Africa” which includes identifying successful Chinese experience and technology to assist in the development of Africa. Since 2017, Dr. Yip has served as a special advisor focusing on health and clean energy for bgC3, a think-tank headed by Bill Gates.  

Dr. Yip served at the faculty of the University of California-San Francisco between 1990 and 1994 and was an adjunct professor at the Friedman School and Nutrition Science and Policy of Tufts University between 2006 and 2010. Currently, Dr. Yip is an adjunct professor at the Research Centre for Public Health of Tsinghua University.  

Dr. Yip graduated from the Medical School and the School of Public Health of the University of Minnesota, and he was then certified as a pediatric haematologist-oncologist.


Independent Non-Executive Directors

Mr. Chan Bing Woon, SBS, JP, (“Mr. Chan”), aged 73, is an independent non-executive Director. He is also a member of each of the Audit Committee, Nomination Committee and Remuneration Committee. Mr. Chan joined the Group in March 2014. Mr. Chan is a consultant of Yung, Yu, Yuen & Co., Solicitors and Notaries. He has over 40 years’ experience in the legal profession. Mr. Chan has been involved in numerous public duties including being Advisor of the Joint Mediation Helpline Office. He is also a fellow member of the Hong Kong Institute of Directors, a council member of the Hong Kong Society of Notaries, a general accredited mediator of Hong Kong International Arbitration Centre and the Law of Society of Hong Kong, and the chairman of the Hospital Governing Committee of Castle Peak Hospital and Siu Lam Hospital. Mr. Chan was a member of the Hospital Authority and a past chairman of the Hong Kong Mediation Council. He is currently an independent non-executive director of Kwoon Chung Bus Holdings Limited (the shares of which are listed on the Main Board of the Stock Exchange, stock code: 306).


Mr. Wong Yiu Kit Ernest (“Mr. E Wong”), aged 50, is an independent non-executive Director. He is also the member of each of the Audit Committee, Nomination Committee and Remuneration Committee. Mr. E Wong joined the Group in February 2017. He has over 25 years of experience in venture capital, corporate finance, business development and general management. Mr. E Wong has served as the president and group chief financial officer of KVB Kunlun Holdings Limited (“KVB”) since November 2011 and as the chief financial officer and the company secretary of KVB’s group company, KVB Kunlun Financial Group Limited (the shares of which are listed on the Stock Exchange, HKEx stock code: 8077) since October 2014. Mr. E Wong has also served as an independent non-executive director of Renheng Enterprise Holdings Limited (HKEx stock code: 3628) since October 2011, HongDa Financial Holding Limited (HKEx stock code: 1822) since July 2014, Legend Strategy International Holdings Group Company Limited (HKEx stock code:1355) since November 2016 and Progressive Path Group Holdings Limited (HKEx stock code: 1581) since November 2016.

Mr. E Wong also served several positions at Adamas Finance Asia Limited (LSE stock code: ADAM), including its executive director from May 2008 to February 2014, its chief financial officer from May 2008 to October 2011 and its non-executive director since February 2014.

Mr. E Wong obtained a bachelor’s degree in business administration from The University of Hong Kong in 1991, a master’s degree of science in investment management from The Hong Kong University of Science and Technology in 1998 and a master’s degree of science in electronic engineering from The Chinese University of Hong Kong in 2008.

Mr. E Wong was admitted as a fellow member of the Association of Chartered Certified Accountants and the Hong Kong Institute of Certified Public Accountants in November 1999 and October 2002, respectively. He was admitted as a chartered financial analyst of the Institute of Chartered Financial Analysts in September 1998 and an associate member of the Institute of Chartered Accountants in England and Wales in January 2008. He is also acting as the president of the Hong Kong University Graduates Association, the deputy chairman of the HKU Convocation, the court member of The University of Hong Kong, a committee member of the Association of Chartered Certified Accountants Hong Kong and an executive director of the Hong Kong Society of Financial Analysts.


Dr. Fang Jun (“Dr. Fang”), aged 55, is an independent non-executive Director. He is also a member of each of the Audit Committee, Nomination Committee and Remuneration Committee. Dr. Fang joined the Group in December 2017. He served as an executive member and the executive vice-chairman of the Cross-straits Medicine Exchange Association of the National Health and Family Planning Commission of the PRC* (中华人民共和国国家卫生和计划生育委员会海峡两岸医药卫生交流协会), an executive member and the vice-chairman of China Sexology Association* (中国性学会), the publisher and the executive chief editor of the China Sexology Journal* (《中国性科学》) and the deputy head of the Sexology Research Center of Peking University Health Science Center* (北京大学医学部性学研究中心). Dr. Fang also assumed various positions such as the executive member and the secretary general of Wu Jieping Medical Foundation (吴阶平医学基金会). Dr. Fang graduated from Peking University Health Science Center with a master’s degree in Social Medicine and Health Service Management and a doctorate degree in Epidemiology and Health Statistics.

Dr. Fang is also an independent non-executive director of HongDa Financial Holding Limited, a company listed on the Stock Exchange (1822.HK).


Biographical details of Directors were updated until 1 June 2018

List of Directors and their Role and Function Read More

Board Committees :
  1. Audit Committee
    • Mr. Wong Yiu Kit Ernest (chairman)
      Mr. Chan Bing Woon, SBS, JP
      Dr. FangJun
      Terms Of Reference
  2. Nomination Committee
    • Dr. FangJun (chairman)
      Mr. Chan Bing Woon, SBS, JP
      Mr. Wong Yiu Kit Ernest
      Terms Of Reference
  3. Remuneration Committee
    • Dr. FangJun (chairman)
      Dr. Ray Yip
      Mr. Chan Bing Woon, SBS, JP
      Mr. Wong Yiu Kit Ernest

      Terms Of Reference

IR Contact

China Regenerative Medicine International Limited

A:

Rooms 3006–10, 30/F., China Resources Building, 26 Harbour Road, Wanchai, Hong Kong

E: info@crmi.hk|

T: +852 3966 8388 |

F: +852 2802 0026